Cover |
12 Months Ended |
|---|---|
|
Dec. 31, 2024
shares
| |
| Document Information [Line Items] | |
| Document Type | 20-F/A |
| Document Registration Statement | false |
| Document Annual Report | true |
| Document Transition Report | false |
| Document Financial Statement Error Correction [Flag] | false |
| Document Shell Company Report | false |
| Entity Interactive Data Current | No |
| Document Accounting Standard | International Financial Reporting Standards |
| ICFR Auditor Attestation Flag | false |
| Amendment Flag | true |
| Amendment Description | Tiziana Life Sciences Ltd. (the “Company”) is filing this Amendment No. 1 to its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Amendment No. 1”), which was originally filed with the Securities and Exchange Commission (the “SEC”) on May 6, 2025 (the “Original Filing”). The purpose of this Amendment No. 1 is to include recent information regarding our clinical program and to correct Exhibit numbers 12.1 and 13.1.In order to comply with certain requirements of the SEC’s rules in connection with this filing, this Amendment No. 1 includes an update in Item 3 Key Information. Consistent with the rules of the SEC, the certifications of the Company’s principal executive officer and principal financial officer as of the date of this Amendment No. 1 are attached as exhibits to this Amendment No. 1.Except as described above, no other changes have been made to the Original Filing. This Amendment No. 1 speaks as of the filing date of the Original Filing. Other than as stated otherwise, this Amendment No. 1 does not, and does not purport to, amend, update or restate any other information or disclosure included in the Original Filing, or reflect any events that have occurred since the date thereof. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing and any documents filed with or furnished to the SEC by the Company subsequent to May 6, 2025. |
| Document Period End Date | Dec. 31, 2024 |
| Document Fiscal Year Focus | 2024 |
| Document Fiscal Period Focus | FY |
| Entity Information [Line Items] | |
| Entity Registrant Name | Tiziana Life Sciences Ltd |
| Entity Central Index Key | 0001723069 |
| Entity File Number | 000-00000 |
| Entity Incorporation, State or Country Code | D0 |
| Current Fiscal Year End Date | --12-31 |
| Entity Well-known Seasoned Issuer | No |
| Entity Voluntary Filers | Yes |
| Entity Current Reporting Status | No |
| Entity Shell Company | false |
| Entity Filer Category | Non-accelerated Filer |
| Entity Emerging Growth Company | false |
| Entity Contact Personnel [Line Items] | |
| Entity Address, Address Line One | Clarendon House |
| Entity Address, Address Line Two | 2 Church Street |
| Entity Address, City or Town | Hamilton HM |
| Entity Address, Country | BM |
| Entity Address, Postal Zip Code | 11 |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | Common Shares |
| No Trading Symbol Flag | true |
| Security Exchange Name | NASDAQ |
| Entity Common Stock, Shares Outstanding | 111,462,617 |
| Business Contact [Member] | |
| Entity Contact Personnel [Line Items] | |
| Contact Personnel Name | Keeren Shah |
| Entity Address, Address Line One | 14-15 Conduit Street |
| Entity Address, City or Town | LondonW1S |
| Entity Address, Country | GB |
| Entity Address, Postal Zip Code | 2XJ |
| Entity Phone Fax Numbers [Line Items] | |
| City Area Code | +44 |
| Local Phone Number | 20 7495 2379 |